Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Sep;1(1):37–43. doi: 10.18383/j.tom.2015.00115

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 The Authors. Published by Grapho Publications, LLC

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Figure 4. — Progression-free and overall survival. (A) Kaplan-Meier curves showing significantly lower PFS in patients with ADC_L < 1.0 μm²/ms (log-rank, P < .0001; Cox multivariate, P = .0002). (B) Kaplan-Meier curves showing significantly lower PFS in patients with ADC_H < 1.6 μm²/ms in univariate analysis (log-rank, P = .0012); however, ADC_H was not significant in multivariate analysis (Cox multivariate, P = .9498). (C) Kaplan-Meier curves showing significantly lower OS in patients with ADC_L < 1.0 μm²/ms (log-rank, P = .0002; Cox multivariate, P = .0487). (D) Kaplan-Meier curves showing significantly lower OS in patients with ADC_H < 1.6 μm²/ms in univariate analysis (log-rank, P = .0487) but not when accounting for age and ADC_L (Cox multivariate, P = .5478). (E) Kaplan-Meier curves showing differences in OS based on ADC_L higher or lower than 1.0 μm²/ms for both bevacizumab-naïve (log-rank, P = .0130) and bevacizumab-treated (log-rank, P = .0029) patients at recurrence. No differences in OS were observed between patients treated with bevacizumab and those who were not within high ADC_L (log-rank, P = .1977) or low ADC_L (log-rank, P = .8959) groups. (F) Kaplan-Meier curves showing no differences in OS based on ADC_H higher or lower than 1.6 μm²/ms for both bevacizumab-naïve (log-rank, P = .1330) and bevacizumab-treated (log-rank, P = .1510) patients at recurrence.